drugset / Trial / NCT06036121
A Study of ADRX-0706 in Select Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Timeline
- Start
- 2023-09-26
- Primary completion
- 2025-09
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADRX-0706 | Other / unclassified | — | — |